Kyowa Kirin plots modest mid-term growth amid competitive challenges
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin has set itself a modest but perhaps realistic goal in its new group mid-term business plan: to grow its pharmaceutical business by 4% over the next three years.